As Expected, CytRx Will Spin Out Its RNAi Drug Operations; Can It Find the Cash to Do It? | GenomeWeb

CytRx will spin out its RNAi-drug programs into a separate business after an internal analysis of its business concluded that the technology could gain better traction in the marketplace if it is developed outside the company, CytRx said this week.

CytRx said that it will transfer all of its RNAi therapeutic assets into a new subsidiary, which is expected to be established "in the coming months … subject to obtaining financing." The company said it anticipates owning a "significant" stake in the new firm.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.